Liquid Biopsy: A Minimally Invasive Tool for Cancer Detection, Monitoring, and Treatment Guidance
What Is a Liquid Biopsy?
A liquid biopsy analyzes cancer-derived material—circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), exosomes, or RNA—from a standard blood draw. It complements, but does not yet replace, tissue biopsy for primary diagnosis.
How It Works
- Sample collection: Peripheral blood draw (10–20 mL).
- Isolation: Separation of plasma/serum and enrichment of tumor-derived analytes.
- Molecular analysis: Next-generation sequencing (NGS), digital PCR, or methylation profiling to detect mutations, copy number changes, fragmentation patterns, or methylation signatures.
- Bioinformatic interpretation: Variant calling, tumor fraction estimation, and clinical reporting.
Key Clinical Applications
- Early detection / screening: Multi-cancer early detection (MCED) tests (e.g., Galleri) for asymptomatic individuals—still under evaluation for population screening.
- Therapy selection: Identifying actionable mutations (e.g., EGFR, PIK3CA, ESR1, BRCA) when tissue is insufficient or unavailable.
- Minimal residual disease (MRD) monitoring: Detecting ctDNA after curative-intent surgery to identify patients at high recurrence risk and guide adjuvant therapy decisions.
- Treatment response tracking: Serial ctDNA levels correlate with tumor burden; early molecular response predicts radiographic outcomes.
- Resistance mechanism detection: Identifying emergent mutations (e.g., EGFR T790M, ESR1 mutations) to guide therapy switches.
Limitations and Considerations
- Sensitivity: Limited by tumor fraction; may miss low-burden or non-shedding tumors.
- Specificity: Clonal hematopoiesis of indeterminate potential (CHIP) can mimic tumor mutations.
- No histologic or microenvironment data: Cannot assess tumor architecture, immune infiltrate, or protein expression (e.g., HER2, PD-L1).
- Standardization: Assay platforms, bioinformatics pipelines, and reporting thresholds vary.
Liquid biopsy is a rapidly evolving field. Current guidelines (NCCN, ESMO, ASCO) endorse specific uses (e.g., EGFR testing in NSCLC, MRD in colorectal cancer) while acknowledging investigational status for broader applications. Always interpret results in clinical context with a molecular tumor board or specialist.
Urine Therapy - Related Articles
- Pet Urine & Babies: Health Risks & What to Do
- Urinalysis: Why It's Ordered and What It Reveals
- Sump Pump Pit Hygiene: Why You Shouldn't Urinate There
- When to Remove a Urinary Catheter: Clinical Decision-Making Guide
- Urinary Bladder: Anatomy, Physiology & Clinical Relevance
- Nocturnal Incontinence in Men: Causes, Evaluation, and Treatment Options
- The Urination Process: How Your Body Produces, Stores, and Eliminates Urine
